Trial Profile
Study of teverelix la, a Gnrh antagonist, in patients with benign prostatic hyperplasia (Bph) (Clinical Trial Ep-24332T-A012)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 May 2018
Price :
$35
*
At a glance
- Drugs Teverelix (Primary)
- Indications Benign prostatic hyperplasia
- Focus Therapeutic Use
- 21 May 2018 Primary endpoint (Reduction in I-PSS) has been met, according to the results presented at the 113th Annual Meeting of the American Urological Association
- 21 May 2018 Results presented at the 113th Annual Meeting of the American Urological Association
- 21 May 2018 New trial record